Articles tagged with Molecular Imaging
Researchers used PET myocardial perfusion imaging to quantify myocardial blood flow and flow reserve, successfully detecting cardiac allograft vasculopathy and predicting prognosis. The study found MFR had higher accuracy in predicting overall prognosis for cardiac transplant patients.
Researchers have identified several potentially useful breast cancer biomarkers that indicate the presence and risk of malignancy. PET/MRI imaging revealed differences in biomarkers between healthy contralateral breast tissue of patients with malignant and benign breast tumors.
Researchers at Helmholtz Munich have created a technique called Mid-infraRed Optoacoustic Microscopy (MiROM) that provides real-time images of biomolecules in living cells without the need for labels or contrast agents. This method offers novel insights into metabolic processes and can be used to study the effects of different diets on...
Researchers developed a novel noninvasive imaging technique using multispectral optoacoustic tomography (MSOT) and ultrasound to diagnose thyroid disorders. MSOT/ultrasound images revealed significant biomarker changes in Graves' disease and malignant thyroid nodules, showing promise for improved diagnostics.
A new study finds that 68Ga-DOTATATE PET/CT is a more accurate method for selecting patients with neuroendocrine tumors who may benefit from peptide receptor radionuclide therapy. The imaging modality yields significantly higher Krenning scores and detects eligible patients with smaller lesions.
A new dual imaging approach combines transrectal ultrasound (TRUS) and photoacoustic imaging to detect anatomical features and molecular information of the prostate. This technology has shown promise in detecting prostate cancers with high accuracy, including distinguishing malignant regions in patients with advanced disease.
The Journal of Nuclear Medicine has seen a significant increase in its impact factor, with a jump of 25% compared to the previous year. The journal's immediacy index also increased, indicating a faster pace of citation activity.
Researchers have developed ultrasmall nanoclusters with antioxidative properties that can pass through the kidneys' filtration barrier to alleviate clinical symptoms of AKI. Selenium-doped carbon quantum dots also demonstrated effective treatment and prevention of AKI in mice by localizing in the kidneys and eliminating ROS.
A novel radiotracer has been identified that can detect nearly 30 types of cancer using positron emission tomography/computed tomography (PET/CT). This technology shows promise for new applications in noninvasive diagnosis, staging and treatment.
Research presented at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting found that tobacco smokers have reduced neuroimmune function compared to nonsmokers. This impairment may contribute to compulsive drug use and cognitive dysfunction in smokers trying to quit.
The Society of Nuclear Medicine and Molecular Imaging announced 13 new SNMMI Fellows, recognizing their outstanding contributions to the field. The recipients include past SNMMI presidents and experts in various areas of nuclear medicine and molecular imaging.
Researchers found PRRT to be safe and effective for patients with grade 3 neuroendocrine neoplasms, with a median progression-free survival rate of 9.6 months and overall survival rate of 19.9 months. Patients with low Ki-67 index responded more favorably to PRRT.
A novel combination therapy using two targeted treatments has shown to maximize efficacy while reducing side effects in men with progressive prostate cancer. The study found that nearly 70 percent of patients saw a more than 50 percent reduction in PSA levels after the treatment.
Researchers developed a wearable vest to collect data for personalized therapy in patients with metastatic NETs. The device provides organ-specific measurement recordings within the patient's comfort, allowing for more effective treatment and improved progression-free survival.
A study using PET imaging reveals that women with the ApoE 4 allele are more susceptible than men to tau accumulation in the brain. The study also found that sex modulates the effect of ApoE ε4 on brain tau depositing in individuals with mild cognitive impairment.
A new class of radiopharmaceuticals, named radiohybrids (rh), has been developed for cancer imaging and radioligand therapy (theranostics). These rhPSMA-ligands have a unique feature that both fluorine and the metal are always present, but only one of them is present as a radioactive isotope.
A study found that PET/CT imaging can identify diseased areas in patients with extra-pulmonary tuberculosis, guiding personalized therapy. The test provides a whole-body survey, helping to estimate disease extent and predict treatment response.
Researchers used PET/CT to evaluate coronary microvascular function in OSA patients and found a link between severe sleep apnea and impaired coronary flow reserve. The study suggests that patients with severe OSA should receive PET myocardial perfusion imaging to exclude coronary microcirculatory dysfunction.
Research shows that adding an interim scan during therapy can help guide patient treatment, predicting survival and tumor response. Interim scans using PSMA PET imaging have shown significant predictive value for overall survival in patients undergoing 177Lu-PSMA radioligand therapy.
A first-in-human Phase 1/Phase II study demonstrates the safety and efficacy of intravenous administration of technetium-99m tilmanocept for monitoring rheumatoid arthritis disease activity. The imaging agent binds to activated macrophages, providing joint-specific information on RA disease involvement.
Jason S. Lewis, PhD, has received the 2019 Paul C. Aebersold Award from the Society of Nuclear Medicine and Molecular Imaging (SNMMI) for his outstanding contributions to basic nuclear medicine science. His research focuses on developing radiopharmaceuticals for targeted diagnosis and treatment of cancer.
Di Carli is recognized as an outstanding clinician-scientist, teacher, and mentor, known for pioneering work in cardiovascular radionuclide imaging and services. His research has contributed to understanding ischemic cardiac dysfunction and using positron emission tomography (PET) for guiding management of patients with end-stage heart...
Researchers developed a new type of nuclear medicine scan that quickly and precisely diagnoses inflammation in IBD using monoclonal antibodies directed against specific innate immune cell markers. The immuno-PET scan has high potential for theranostic diagnosis and precision treatment of IBD and other inflammatory diseases.
A multicenter study found that deep learning analysis of single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI) improved the diagnosis of obstructive coronary artery disease. The new method showed increased sensitivity and accuracy compared to traditional methods, leading to better patient outcomes.
A 12-year retrospective clinical study shows the long-term effectiveness of PRRT, allowing patients to maintain a high quality of life. The overall response rate is about 70-80 percent, and prognosis is generally favorable for patients who respond to therapy.
The first total-body PET/CT scanner has shown promising results in enhancing image quality, reducing scan time, and lowering dose. Clinical trials have demonstrated improved diagnostic capabilities with minimal impact on patient exposure.
Researchers have identified two new nuclear medicine tracers that provide high-contrast images for cancer diagnosis, allowing for shorter imaging times and no diet changes. The tracers target cancer-associated fibroblasts, promoting tumor growth, migration, and progression.
Researchers have developed a novel PET/CT tracer that detects and characterizes blood clots in the legs, where conventional imaging has limitations. The new imaging agent may provide more accurate diagnoses and information on clot growth or embolization, leading to changes in clinical intervention.
Researchers have found that a new PET imaging agent, 18F-FFNP, can measure changes in progesterone receptor levels resulting from hormone therapy for breast cancer patients. This could provide an earlier indicator of therapy effectiveness and inform individualized treatment decisions.
A new PET probe targets melanin pigment in skin cancer lesions to improve detection of primary and metastatic melanoma. The probe shows promising results in clinical trials, outperforming existing methods like 18F-FDG PET/CT scans.
PSMA-targeted PET/MRI performs equally well as clinical nomograms to determine risk for advanced disease in high-risk prostate cancer patients, providing valuable information for treatment planning. The study results show whole-body imaging with 68Ga-PSMA-11 PET/MRI offers a one-stop shop for staging and guiding treatment options.
A new second-generation positron emission tomography (PET) tracer has been identified for imaging tau pathology in Alzheimer's disease patients. The tracer, 18F-RO-948, showed promising results in a human evaluation study, outperforming other novel tau-specific radiopharmaceuticals.
Researchers developed a novel SPECT tracer to image c-Met expression in NSCLC, producing clearer images in less time and reducing radiation exposure. The tracer showed high specificity and rapid clearance from the body, making it potentially suitable for clinical use.
Researchers developed a hybrid nanoplatform that locates tumors using three different types of contrast simultaneously, facilitating multimodal molecular medical imaging. The platform overcomes the limitations of single image modality while maximizing their advantages.
A new preclinical study shows that PET imaging with the 18F-FAC radiotracer can image T cells in the liver, potentially reducing biopsies and improving treatment. The approach could lead to personalized treatment of patients with immune-related liver disease.
A new PET imaging radiotracer, <sup> 18 </sup> F-XTRA, was tested on adults to study the distribution of the α4β2 nicotinic acetylcholine receptor in the brain. The research found that the radiotracer rapidly entered the brain and distributed quickly, with lower binding in the hippocampus with healthy aging.
Dr. Robert Gillies, chair of Cancer Physiology and Radiology Research at Moffitt Cancer Center, receives the World Molecular Imaging Society's Gold Medal Award for his lifetime research in molecular imaging. His work focuses on understanding cancers as complex systems, leading to new cancer treatment options.
A recent study highlights the potential for misinterpretation of Prostate-Specific Membrane Antigen (PSMA) PET results, which can affect diagnostic accuracy and guide therapy. Researchers urge nuclear medicine physicians to analyze PSMA-ligand uptake in conjunction with lesion localization to avoid misdiagnosis.
Researchers used a PET tracer to identify differences in ER expression across metastases and surrounding normal tissue in breast cancer patients. The study found that approximately 50% of patients had one or more estrogen-receptor negative lesions, highlighting the heterogeneity of ER expression.
Researchers have developed a novel PET imaging method that can measure beta-cell mass, enhancing the ability to monitor and guide diabetes therapies. The new imaging method uses a radioligand to identify beta cells and has shown promising results in differentiating between healthy individuals and those with type 1 diabetes.
The Society of Nuclear Medicine and Molecular Imaging's Technologist Section recognized contributions from April Mann, Cybil Nielsen, Cheryl Rickley, and Lynne Roy for their dedication to advancing nuclear medicine technology. The awards highlight the impact of these individuals on education, advocacy, and service in the field.
The Journal of Nuclear Medicine's impact factor increased by 12% in 2017, ranking fifth among medical imaging journals. Citations to the journal rose from 24,977 to 27,101.
A novel, affibody-based pretargeted radionuclide therapy for HER2-expressing cancers demonstrated non-toxicity to the kidneys and improved survival in mice. The treatment delivered an absorbed dose to tumors that exceeded the dose to critical organs.
The Society of Nuclear Medicine and Molecular Imaging's 65th Annual Meeting showcased advancements in theranostics, quantitative nuclear imaging, and multimodality molecular imaging. Key findings include improved diagnostic accuracy and treatment options for various diseases, highlighting the potential for precision health.
A study presented at the SNMMI Annual Meeting found that early treatment of advanced prostate cancer with lutetium-177 radioligand therapy can significantly prolong life, with a median overall survival of 27 months. Patients who received first-line therapy also had the longest survival rates.
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) announced the selection of 14 new Fellows, recognizing their excellence in volunteer service, scientific discovery, and clinical practice. The SNMMI Fellowship is one of the most prestigious formal recognitions available to long-time members.
A clinical trial found that 59% of patients with biochemical recurrence of prostate cancer had their clinical management changed by fluciclovine PET/CT imaging. The study detected disease in the prostate, pelvic lymph nodes, and less commonly, bone, guiding treatment decisions for men with recurrent prostate cancer.
Researchers found improved quality of life and reduced tumor spread in patients treated with LuPSMA therapy. PSMA PET imaging demonstrated exceptional responses, correlating with significant reductions in PSA levels.
Researchers have developed a novel approach to pretargeted radioimmunotherapy, which has shown complete responses in several solid tumor types using the beta-emitting lutetium-177 and alpha-emitting actinium-225. The new approach offers greater versatility of treatment for various solid tumors and clinical situations.
A new molecular imaging method allows early assessment of gene therapy success, potentially improving treatment for Parkinson's and Alzheimer's diseases. The PET reporter gene/probe system enables noninvasive monitoring of gene expression in all brain areas.
A new long-lasting type of radionuclide therapy has been proven effective in treating advanced neuroendocrine tumors, with the treatment lasting up to 4 times longer than previous options. The therapy, Lutathera-177 (Lu-DOTA-EB-TATE), was well-tolerated and showed promising results in a Phase I trial.
A novel intelligent theranostic agent was designed to target tumors, with the ability to self-assemble in the tumor microenvironment and activate for therapy guided by photoacoustic imaging. The clusters showed high selectivity to the tumor microenvironment and eliminated tumor growth without subsequent recurrence.
Gambhir's work on multimodality molecular imaging has advanced nuclear medicine and healthcare. He has developed strategies to study gene and cell therapies, and his lab has more than 625 publications and over 40 patents pending.
Simon Cherry has made significant contributions to biomedical imaging instrumentation and technology development, including microPET and hybrid PET/MRI systems. He is widely recognized for his work on molecular imaging and has received numerous awards for his achievements.
Researchers have developed a novel nuclear medicine probe that can detect synaptic density loss in the brain, a key biomarker for neurodegenerative diseases like Alzheimer's. The probe, using positron emission tomography (PET) imaging, has high imaging characteristics and is suitable for clinical trials and commercialization.
Researchers have demonstrated that combining targeted radionuclide therapy with immunotherapy can enhance treatment response and lead to a high cure rate in melanoma patients. This novel approach uses yttrium-86 (Y-86) NM600, which selectively targets tumors and delivers precise radiation doses.
Richard L. Wahl, MD, has been recognized for his pioneering work in radioimmunotherapy, PET scans, and fusion imaging. His research has significantly contributed to understanding cancer prognosis, treatment response, and the importance of metabolic activity.
Researchers developed a novel PSMA-targeting agent by conjugating MCG with an albumin-binding Evans blue derivative, improving tumor delivery and increasing the therapeutic effect. The agent showed significant tumor growth inhibition and complete eradication of tumors in mice, suggesting a promising strategy for cancer management.
A novel PET tracer has been developed to accurately image cardiovascular infections, which are extremely dangerous and have a high fatality rate. The tracer, called 6'-[18F]Fluoromaltotriose, is transported into bacterial cells by a membrane transport system exclusive to bacteria, allowing for specific imaging of bacterial infections.
A novel PET imaging method uses antibody fragment probes to target immune cells, detecting inflammation in the bowel and potentially guiding biopsies. The technique has wide applications in various diseases and could unlock assessment of inflammation.